IL6 and neoplasm: identify IL-6 as a correlate of poor clinical response to atezolizumab (anti-PD-L1) therapy and demonstrate that IL-6 impairs anti-PD-L1 efficacy by restricting the anti-tumor functions of cytotoxic T cells.